Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Welcome to the Zombie-land Of Investing - Part II

In Part I of this research post, we highlight how the ES and Gold reacted 24+ months prior to the 2007-08 market peak and subsequent collapse in 2008-09. The point we were trying to push out to our followers was that the current US stock market indexes are acting in a very...

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. Beaker In a May 20 research report, ROTH Capital Partners analyst Yasmeen Rahimi reported that The Medicines Company's (MDCO:...

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its e...

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...

The Impact of Monetary Policy on Gold

In March, the World Gold Council released the newest edition of its Investment Update . What can we learn from the publication? Let’s examine the most recent history of Fed tightening and loosening with respect to its effect on gold prices. Is Fed&CloseCu...

Acquisition of Nevada Properties 'Extends Asset Growth Potential'

A description of the properties and how this precious metals company will benefit from their addition are provided in a CIBC report. In a June 27 research note, CIBC analyst Cosmos Chiu reported that SSR Mining Inc. (SSRM:NASDAQ) acquired two past-prod...

FedEx Shares Down 13.5% on Earnings and Global Trade Concerns

FedEx Corp. shares are trading much lower today after it reported Q1/20 earnings. The firm confirmed it will raise prices by 4.9% to 5.9% in January 2020. After the close of trading yesterday express air freight carrier FedEx Corp. (FDX:NYSE) announced consolidated...

Buzz on the Bullboards: Feeling the tech selloff?

It has been a turbulent week on Bay Street and Wall Street. Canada’s commodity-heavy main stock index tumbled this week, weighed down by a near 5% drop in crude prices on demand concerns, while bullion prices slipped to a four-week low further hurting...

Metals React To Fed Shockwaves – Ready For Next Move

On July 31, 2019, the US Federal Reserve decreased the Federal Funds Rate (FFR) by 25 basis points. We believe the US Fed was pushed to take this action for three reasons that are directly related to the fear and greed that is abundant in the global markets. Reason #1 Fed H...

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
1 2 3 4 5 6 7 8 9 10 ...